Less is more in PET-negative, advanced HLJune 28, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
CSF p-Tau predicts neurocognitive sequelae in survivors of childhood cancerJune 28, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin LymphomaAggressive Lymphomas
Brentuximab meets phase 3 primary endpoint in frontline advanced HLJune 27, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
New SC rituximab formulation approved, reduces administration timeJune 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Kids’ self-reports of symptoms, side effects reliableJune 24, 2017Lymphoma & Plasma Cell DisordersHematology NursingRelated Issues
Chemo-free triplet produces ‘favorable’ results in advanced diseaseJune 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Inhibitor elicits responses in heavily pretreated FL, DLBCLJune 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
New frontline treatments needed for Hodgkin lymphomaJune 22, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Fostamatinib under review by FDA for chronic ITPJune 21, 2017AnemiaThrombosisPharmacyBleeding Disorders
Company discontinues phase 3 trial of vadastuximab talirine in AMLJune 20, 2017Leukemia, Myelodysplasia, TransplantationAMLMyelodysplastic Syndrome
Biosimilar rituximab approved in EuropeJune 20, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
